Regencell Bioscience (NASDAQ:RGC) Trading Up 6.7% - Time to Buy?

Key Points

• Regencell Bioscience shares rose 6.7% to about $5.87 in Wednesday trading, though volume was approximately 80% below the stock’s average daily level.
• Analyst sentiment remains negative: Weiss Ratings reiterated a “sell” rating, Wall Street Zen downgraded the stock to “sell,” and MarketBeat reports a consensus “Sell” rating.
• Institutional ownership is minimal at just 0.13%, despite recent stake increases or new positions from firms including Bank of America, Amundi, and Vident Advisory.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s share price was up 6.7% during trading on Wednesday . The company traded as high as $5.86 and last traded at $5.8710. Approximately 58,345 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 296,605 shares. The stock had previously closed at $5.50.

Analyst Upgrades and Downgrades

RGC has been the topic of a number of recent research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. Wall Street Zen lowered shares of Regencell Bioscience from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of "Sell".

Regencell Bioscience Trading Up 5.9%

The firm has a fifty day moving average of $5.80 and a 200-day moving average of $18.66.

Hedge Funds Weigh In On Regencell Bioscience

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company's stock valued at $437,000 after acquiring an additional 17,143 shares during the last quarter. Amundi bought a new stake in shares of Regencell Bioscience in the 1st quarter valued at about $219,000. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience in the 4th quarter valued at about $92,000. Vident Advisory LLC lifted its stake in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in Regencell Bioscience in the 4th quarter valued at about $275,000. 0.13% of the stock is currently owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source